A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Clinical Trial

Official title:

A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 Following Multiple Dose Administrations in Participants With Mild-to-Moderate SLE

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05866861
• Other study ID #: CUG252-P102
• Status: Recruiting
• Phase: Phase 1
• Start date: April 24, 2023
• Est. completion date: July 2024

Study information

• Verified date: May 2023
• Source: Cugene Inc.
• Contact: Cugene, Inc.
• Phone: 781-893-5800
• Email: info[@]cugene.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety and tolerability of CUG252 following multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).

Description:

CUG252 is a potential best-in-class engineered IL-2 compound, designed to have improved Treg selectivity while reducing undesired IL-2 activity.

This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunologic effects of CUG252 following subcutaneous administration of multiple ascending doses in participants with mild-to-moderate SLE. The effects of SLE disease activity and biomarkers will also be evaluated.. The SLE participants will receive randomized multiple subcutaneous doses of CUG252 or placebo. After receiving the last dose of CUG252 or placebo, participants will be followed to study day 64 post first dose administration to evaluate safety, PK, PD and preliminary efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female participant, aged 18 to 65 years (inclusive), at time of consent

• BMI greater than or equal to 18 and less than 39 kg/m2 at Screening

• Diagnosis of SLE at least 6 months prior to Screening

• Minimal to moderate SLE disease activity

• If a participant is taking oral prednisone, the dose must be less than or equal to 20 mg/day for a minimum of 8 weeks prior to Screening and at a stable dose for a minimum of 2 weeks prior to Screening

• If a participant is taking azathioprine, antimalarial, mycophenolate mofetil, or methotrexate, the medication(s) must have been started a minimum of 12 weeks prior to Screening and at a stable dose for a minimum of 8 weeks prior to Screening

Exclusion Criteria:

• Have one or more of the following medical conditions: SARS-CoV-2 infection 30 days prior to drug administration, evidence of Grade 3 or greater hematologic, hepatic, or rental dysfunction, active severe or unstable neuropsychiatric SLE, active severe renal disease, history of severe active lupus nephritis with proteinuria levels greater than 1.0 g/24 hours, or dialysis in the last 6 months. History of current diagnosis of other autoimmune/inflammatory diseases, history of any non-SLE disease that has required treatment with corticosteroids for more than 2 weeks within the last 12 weeks prior to Screening, active clinically significant bacterial, viral, or fungal infection at Screening, active or latent TB at Screening, pulmonary infection or active lung disease besides those related to lupus, or severe pulmonary disease requiring oxygen therapy. History of condition that predisposes participant to infection, confirmed positive serology at Screening, history of opportunistic infection requiring hospitalization or IV antimicrobial treatment within the last year, history of organ or hematopoietic stem cell transplant, history of major surgery within 12 weeks of Screening, history of significant cardiovascular disease, history of gastrointestinal bleeding, history of cancer apart from successfully treated squamous or basal cell carcinoma or cervical cancer in situ.

• Are on one or more of the following medications: have received vaccination within 30 days prior to Screening (including COVID-19 vaccination), Aldesleukin or other IL-2 derivatives at any time, T cell depleting agents and inhibitors of T cell activation at any time, Anti-BLyS/BAFF inhibitors, IL-1 receptor antagonist, anti-TNF therapy, and anti-interferon alpha receptor inhibitor within 3 months prior to Screening, rituximab or other B-cell depleting agent within 6 months, glucocorticoids within 6 weeks prior to Day 1, other immunosuppressant drugs within 8 weeks, history of cytotoxic medications within 12 months, receipt of blood products within 6 months, plasmapheresis within 30 days of Screening.

Related Conditions & MeSH terms

• Autoimmune
• Lupus Erythematosus, Systemic
• SLE (Systemic Lupus)
• Systemic Lupus Erythematosus

Intervention

Drug:
• CUG252
CUG252 will be administered by subcutaneous injection.
• Placebo
Placebo will be administered by subcutaneous injection.

Locations

Country	Name	City	State
United States	Site 1001	Anniston	Alabama
United States	Site 1002	Clearwater	Florida
United States	Site 1010	Columbus	Ohio
United States	Site 1006	Dallas	Texas
United States	Site 1003	Duncansville	Pennsylvania
United States	Site 1011	La Jolla	California
United States	Site 1007	Lawrenceville	Georgia
United States	Site 1004	Mesquite	Texas
United States	Site 1005	Middleburg Heights	Ohio
United States	Site 1012	Seattle	Washington
United States	Site 1009	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Cugene Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and percentage of subjects with Treatment Emergent Adverse Events	To evaluate the safety and tolerability of multiple ascending doses (MAD) in participants with mild to moderate SLE.	Up to 64 Days
Secondary	Pharmacokinetics profile of CUG252 (AUC)	To assess the Area under the plasma concentration versus time curve (AUC)	Day 1 pre dose through Day 64
Secondary	Pharmacokinetics profile of CUG252 (Cmax)	To assess the maximum plasma concentration (Cmax)	Day 1 pre dose through Day 64
Secondary	Pharmacokinetics profile of CUG252 (Tmax)	To assess the time of maximum concentration (Tmax)	Day 1 pre dose through Day 64
Secondary	Pharmacokinetics profile of CUG252 (t1/2)	To assess the half-life (t1/2)	Day 1 pre dose through Day 64
Secondary	Immunogenicity of CUG252	To measure the serum concentration of antibodies against CUG252	Day 1 pre dose through Day 64
Secondary	Change in the number and percentages of immune cells	To assess the effect of CUG252 on immuno-pharmacodynamic endpoints.	Day 1 pre dose through Day 64